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However, tumour burden is difficult to measure and there are currently no reliable surrogate
biomarkers to easily and reliably determine it. The aim of this study was to assess the potential
of plasma total cell free DNA as biomarker of tumour burden and prognosis in metastatic
melanoma patients.
Materials and methods: A prospective biomarker cohort study for total plasma circulating cell-
free DNA (cfDNA) concentration was performed in 43 metastatic melanoma patients. For 38
patients, paired blood collections and scan assessments were available before treatment and at
first response evaluation. Tumour burden was calculated as the sum of volumes from three-
dimensional radiological measurements of all metastatic lesions in individual patients.
Results: Baseline cfDNA concentration correlated with pre-treatment tumour burden
(r Z 0.52, P < 0.001). Baseline cfDNA levels correlated significantly with hazard of death
and overall survival, and a cut off value of 89 pg/ml identified two distinct prognostic groups
(HR Z 2.22 for high cfDNA, P Z 0.004). Patients with cfDNA 89 pg/ml had shorter OS
(10.0 versus 22.7 months, PZ 0.009; HRZ 2.22 for high cfDNA, PZ 0.004) and the signif-
icance was maintained when compared with lactic dehydrogenase (LDH) in a multivariate
analysis. We also found a correlation between the changes of cfDNA and treatment-related
changes in tumour burden (r Z 0.49, P Z 0.002). In addition, the ratio between baselinencology Group, Cancer Research UK Manchester Institute, The University of Manchester, Wilmslow
.manchester.ac.uk (R. Marais).
ed by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/
S. Valpione et al. / European Journal of Cancer 88 (2018) 1e92cfDNA and tumour burden was prognostic (HR Z 2.7 for cfDNA/tumour volume 8 pg/
(ml*cm3), P Z 0.024).
Conclusions: We have demonstrated that cfDNA is a surrogate marker of tumour burden in
metastatic melanoma patients, and that it is prognostic for overall survival.
ª 2017 The Authors. Published by Elsevier Ltd. This is an open access article under the CC
BY license (http://creativecommons.org/licenses/by/4.0/).Key Message: Plasma cfDNA level correlates to
tumour volume and is a surrogate biomarker for tumour
burden and a prognostic marker for survival in meta-
static melanoma patients.1. Introduction
Circulating cell-free DNA (cfDNA) is short fragment
(usually 130e180 base pairs) double stranded DNA that
is present in blood and other body fluids [1e4]. Its origin
is thought to be mainly from apoptotic or necrotic cell
death, although active release mechanisms have also
been suggested [5,6]. Increased levels of cfDNA in the
blood are frequently observed in cancer patients and in
some settings increased cfDNA is an adverse prognostic
factor [7]. However, tumours are not the sole source of
cfDNA, and increased levels are also linked to impaired
renal clearance and production of white blood cells
(WBC) [8,9]. Moreover, the mechanisms of cfDNA
release are poorly understood, and their prognostic
value and relationship to tumour burden are contro-
versial [10]. In particular, the correlation between
tumour volume and cfDNA is still under study [11].
One explanation for the current lack of evidence to
directly correlate tumour burden and cfDNA levels is that
precise evaluations of tumour burden are not routinely
performed. This is because assessing tumour burden in
individual patients is demanding and requires time-
consuming procedures to measure all metastatic lesions.
Metastatic load in melanoma is considered an important
prognostic and predictive factor in melanoma and surro-
gate biomarkers are currently used for clinical purposes,
including the number of metastatic sites and Response
Evaluation Criteria in Solid Tumours (RECIST) marker
lesion measurement [12,13]. However, the current version
(RECIST 1.1) relies on mono-dimensional measurements
of no more than 2 lesions per organ and a maximum of 5
lesions selected at the discretion of the radiologist, there-
fore is subject to interpretation bias as demonstratedby the
significant differences often observed between in-
vestigators’ and central review’s assessments in clinical
trials [14e16]. As a consequence, RECIST 1.1 is a poor
tool with which to investigate the relationship between
cfDNA and tumour burden.
One of the most powerful uses of cfDNA is related to
the identification of tumour-specific mutations that are
derived from the cancer cells. The analysis of this
circulating tumour DNA (ctDNA) allows application ofliquid biopsies for personalised strategies [17e20].
Critically however, a clear link between cfDNA or ct
DNA and tumour burden has not been established, and
routine analysis of ctDNA is often unfeasiblebecause it
requires information on the mutational landscape of the
tumour.
In the present study, we examined the relationship
between cfDNA, ctDNA and tumour burden in patients
with metastatic melanoma. We used computed tomog-
raphy (CT) and/or magnetic resonance imaging (MRI)
scans to determine the total tumour burden in the pa-
tients and then compared this to cfDNA levels.
Intriguingly, we did not find a correlation between
ctDNA and cfDNA, but did find a correlation between
cfDNA and tumour burden. Our study shows the po-
tential of cfDNA as biomarker of tumour burden in
metastatic melanoma patients, and we show that cfDNA
is a biomarker for prognosis and response to treatment.
2. Materials and methods
2.1. Patients
A prospective longitudinal biomarker cohort study was
performed in collaboration between Cancer Research
UK Manchester Institute and The Christie NHS
Foundation Trust. Ethical approval was granted by the
Manchester Cancer Research Centre (MCRC) Biobank
Access Committee (Protocol number 13RIMA01). All
patients gave written informed consent. Inclusion
criteria were the diagnosis of metastatic melanoma,
patients naı¨ve for systemic oncological treatments or
with an interval from therapy (in the adjuvant or met-
astatic setting) of at least 2 years, to be longitudinally
followed up during treatment. Patients were studied
with paired blood collections and scan assessments
performed before treatment initiation and at treatment
response evaluation (at 12e16 weeks).
2.2. Tumour burden and response assessment
Tumour burden estimation was performed with
computed tomography (CT), magnetic resonance im-
aging (MRI) or positron-emission tomography coupled
with CT (PET-CT) (slide thickness 3 mm). Scans were
evaluated by a radiologist as per RECIST 1.1 and then
independently reviewed for metastases volume analysis;
Picture Archiving and Communication System
S. Valpione et al. / European Journal of Cancer 88 (2018) 1e9 3Centricity Enterprise Web Viewer (v 3.0, GE Health-
care, Boston, United States of America (US)) was used.
Tumour burden was assessed as the sum of all three-
dimensional metastatic lesions volumes (calculated with
the formula for ellipsoid volumes, as previously
described [18]) visualized at radiological scans. The
maximum interval between blood biomarker analysis
and radiological assessment was 4 weeks at baseline and
less than 2 weeks for treatment response follow-ups. The
variation of plasma cfDNA and tumour burden at
baseline and clinical reassessment was defined as the
ratio between cfDNA concentration at reassessment to
baseline and the ratio of tumour burden at reassessment
to baseline.
2.3. Circulating biomarkers
Blood samples were collected in BD Vacutainer K2E
(EDTA), plasma was separated and frozen within 4 h of
phlebotomy. DNA was extracted from plasma using
QIAamp Circulating Nucleic Acid Kits (Qiagen).
CfDNA was quantified by means of measurement of a
reference gene, RNAseP, by quantitative polymerase
chain reaction (PCR) using the TaqMan RNAseP AssayFig. 1. Method to measure total tumour burden in melanoma patients. Th
an individual patient (patient #36). The scan images of the metastases
plane (measuring the width and depth of the metastases) are reported o
are on the far left (frontal plane) and far right (axial plane). In desce
nodal metastasis (#2), a right peri-common iliac nodal metastasis (#
metastasis was measured in its 3 dimensional orthogonal diameters (A
with the formula for ellipsoids (VolumeZ (diameter A/2)  (diameter
right side of the figure, and then summed.(Life Technologies); in 33 patients, ctDNA was addi-
tionally quantified by means of droplet digital PCR Bio-
Rad QX200 targeted to a specific mutation in melanoma
cells and expressed as variant allele frequency (VAF),
the fraction of mutant droplets among the total number
of mutant and wild-type droplets, as previously
described [17,18]. Lactic dehydrogenase (LDH),
glomerular filtration rate (GFR) (calculated with
Cockroft-Gault formula [21]) and WBC count were
measured during routine clinical diagnostics.
2.4. Statistical analyses
After checking the assumptions of normality distribu-
tion (Anderson-Darling test A Z 0.36, P Z 0.425,
where a P value < 0.05 would reject the hypothesis of
normality; Supplementary Fig. 1 shows the QeQ plot
for the normal distribution test), Pearson test was used
to assess a pairwise correlation between cfDNA and
tumour burden both at baseline and at treatment
response reassessment (minimum sample size to identify
a r value > 0.45, with a Z 0.05 and b Z 0.8 was
calculated 36 patients) and between cfDNA, GFR and
WBC. The multivariate analysis for the relationshipe figure shows the procedure to determine total tumour burden in
on the frontal (measuring the height of the metastases) and axial
n the left and right, respectively. Correspondent magnified images
nding order, patient #36 had a lung metastasis (#1), a peri-aortic
3) and a right peri-bifurcation iliac nodal metastasis (#4). Each
, B and C in the formula below) and then the volumes, calculated
B/2)  (diameter C/2)  p4/3), shown for each metastasis on the
Table 1
Patient demographics and disease characteristics.
Patient characteristic Median (range)
tot Z 43
N (%)
tot Z 43
Sex F:M 18(42):25(58)
Age (years) 58.1 (18e85.1)
Subtype skin:mucosal:undetermined 37(86):3(7):3(7)
LDH (U/L; upper normal
limit Z 550)
467 (268e1780)
BRAF mutation 30 (70)
NRAS mutation 7 (16)
cKIT mutation 1 (2)
No detected mutations (‘wild type’) 5 (12)
Treatment
ipilimumab 15 (35)
BRAF/MEK inhibitor 14 (33)
PD1 inhibitor 11 (26)
DTIC 1 (2)
Progression free survival (months) 4.8 (1.1e15.3)
Overall survival (months) 17.3 (2.8e28.3)
BRAF-mutated overall survival
(months)
10.4 (2.9e19)
NRAS-mutated overall survival
(months)
18.8 (3.8e18.8)
KIT-mutated overall survival
(months)
27.9 (NA)
WT overall survival (months) 22.7 (7.6e22.7)
1-year survival (%) 55.9
DTIC, dacarbazine; LDH, lactic dehydrogenase; cfDNA, cell free
DNA.
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was performed with linear regression (Cohen rule was
used to calculate the sample size with minimum of 34
cases for 3 independent covariates to be tested;
f2 Z 0.35).
KaplaneMeier method was used for survival analysis;
groups were compared with log-rank test. Analysis ofHR
was performed with multivariate Cox regression and
ANOVA to determine the significance level; proportional
hazard hypothesis was verified by Schoenfeld residuals
test resulting PZ 0.984, where P<0.05 would indicate a
violation of the hypothesis residuals and strata for treat-
ment were applied. The ‘rule of the thumb’ was used to
calculate minimum size of 20 events for the prognostic
study. Receiver Operating Curve (ROC) was used to
identify the cut off of baseline cfDNA concentration for
overall survival less than one year.
Enrolment continued to fulfillment of sample size for
all study parts. All patients were included in the prog-
nostic study. 43 patients were included in the baseline
biomarkers study; patients with paired assessments at
baseline and first re-assessment were included in the
biomarker study for tumour burden and treatment
response if the treatment was not stopped or changed in
the meantime, for example because of clinical progres-
sion or toxicity, (N Z 38).
Analyses were performed using R (v. 3.3.3, CRAN
project, Vienna).3. Results
To investigate the relationship between tumour burden
and the levels of total cfDNA in plasma, we first
measured the cumulative volume of all the metastatic
lesions in 38 melanoma patients attending the Christie
Hospital NHS Foundation Trust. To determine tumour
burden, CT or MRI scans were used to identify all of the
lesions in each individual patient, and then we measured
the height, width and depth of each lesion (Fig. 1). These
measurements were used to calculate the volume of the
single lesions, and were then summed to give the tumour
burden for each patient (Fig. 1). Thirty-eight patients
who had received baseline and reassessment scans were
included in the study, and an additional 5 patients,
whose scans were outside the inclusion criteria but for
whom we had cfDNA measurements, were also included
in the prognostic analysis. All of the patients had met-
astatic melanoma, mostly (76%) with stage M1c disease,
the median age was 58 (range 18e85), the distribution of
men and women was roughly equal, and 37% had a
raised LDH (Tables 1 and 2). The mutation status was
studied for driver oncogenes with therapeutic potential
(BRAF, NRAS, KIT ) in this patient population, and the
treatment modalities administered reflect the standard
of care for patients at that time. The median progression
free survival was 4.8 months (range 1.1e15.3) and themedian overall survival was 17.3 months (range
2.9e28.3) (Table 1) with a median follow-up time of
11.9 months. 24 patients have died. The majority (76%)
of the patients presented with primary melanoma in the
skin and subsequently developed multi-organ metastatic
disease (79%). The number of metastatic sites ranged
from 1 to 7 lesions, most commonly in the lymph nodes
(71% of cases), but also in other sites frequently asso-
ciated with metastatic melanoma. The tumour burden
across the cohort ranged from 0.45 cm3 to 310 cm3, with
a median of 20.85 cm3 (Tables 1 and 2).
We measured baseline total cfDNA in the patients’
plasma, and observed a range from 17 pg/mL to
1.125 pg/mL with a median of 135 pg/mL (Table 2). We
found a significant correlation (r Z 0.52, P < 0.001)
between baseline plasma total cfDNA and pre-treatment
tumour burden (Fig. 2A). In contrast, cfDNA levels did
not correlate with GFR (rZ 0.16, PZ 0.339) (Fig. 2B)
or WBC count (r Z 0.14, PZ 0.386) (Fig. 2C). Multi-
ple regression analysis yielded similar results, confirming
cfDNA concentration correlated with tumour burden
(R2 Z 0.36, P < 0.001), but not glomerular filtration
rate or white blood cell count (PZ 0.135 and PZ 0.080
respectively) (the validation of the multiple regression is
shown in Supplemental Fig. S2).
We also compared the relationship between the
change in plasma cfDNA and change in tumour burden
between baseline and first response assessment (w3
months for immunotherapy and w4 months for tar-
geted therapy) and observed a significant correlation
Table 2
Melanoma characteristics and stage of patients analysed for tumour burden.
Patient Stage Baseline
LDH
Number of
metastatic sites
Metastatic sites Baseline tumour
burden (cm3)
Baseline cfDNA
(pg/ml)
1st line therapy OS (months)
#1 M1c high 2 lung, nodes 2.74 213.8 ipilimumab 23
#2 M1a low 1 nodes 115.98 80 ipilimumab 3.8þ
#3 M1c low 2 liver, nodes 5.89 86.6 DTIC 27.9þ
#4 M1b low 3 lung, nodes, soft tissues 3.42 17 ipilimumab 22.7þ
#5 M1c low 3 lung, nodes, bone 24.25 89 ipilimumab 7.6þ
#6 M1c high 1 nodes 95.17 255 BRAFi 4.6þ
#7 M1c low 2 lung, liver 4.98 117 BRAFi 17.3þ
#8 M1c low 2 liver, peritoneal 3.55 44.9 ipilimumab 18
#9 M1c low 2 nodes, bowel 4.78 58.35 ipilimumab 28.3
#10 M1c low 3 liver, nodes, soft tissues 7.25 124 ipilimumab 10.4þ
#11 M1c high 2 liver, peritoneal 0.45 137.7 BRAFi 2.9þ
#12 M1c low 3 adrenal, peritoneal, soft tissues 25.69 64 ipilimumab 18.8þ
#13 M1c high 3 nodes, bone, bowel 2.74 392.7 PD1i 13.4
#14 M1a low 1 nodes 28.94 82.4 ipilimumab 23.8
#15 M1c low 3 liver, nodes, soft tissues 36.64 188 ipilimumab 8.4þ
#16 M1c low 2 nodes, bone 45.15 93 ipilimumab 11.6þ
#17 M1c high 4 liver, peritoneal,
retroperitoneal, soft tissues
310.36 1125.3 BRAFi 5.6þ
#18 M1c low 3 liver, nodes, soft tissues 11.79 130.8 PD1i 12
#19 M1c high 4 lung, liver, nodes, bone 74.78 89 ipilimumab 8.3þ
#20 M1a low 1 soft tissues 25.34 118 ipilimumab 13.2þ
#21 M1c high 7 lung, liver, nodes, bone,
adrenal, omental, soft tissue
16.68 729.9 BRAFi 8.1þ
#22 M1c low 2 lung, bone 75.83 278 BRAFi 8.7þ
#23 M1a low 2 lung, nodes 68.81 144.9 ipilimumab 15.7
#24 M1a low 1 nodes 4.49 270.8 PD1i 14.6
#25 M1c high 1 brain 6.96 819.3 BRAFi 8.5þ
#26 M1c low 3 lung,liver, soft tissues 3.03 199.6 PD1i 14.2
#27 M1a low 1 nodes 13.72 221.2 PD1i 11.3
#28 M1c low 2 peritoneal, soft tissues 1.06 47 PD1i 11.9
#29 M1c high 4 lung, liver, nodes, bone 24.97 621 BRAFi 6.8þ
#30 M1b low 2 lung, nodes 22.94 379.9 PD1i 10.4
#31 M1c low 4 lung, liver, nodes, bone 2.75 91.4 PD1i 10
#32 M1c high 3 lung, nodes, soft tissues 62.28 339.8 BRAFi 19þ
#33 M1c low 2 nodes, soft tissues 48.24 330.3 BRAFi 4.9þ
#34 M1c low 1 nodes 12.08 132.3 BRAFi 10.2
#35 M1b low 2 lung, nodes 32.43 62.6 PD1i 9.5
#36 M1c low 3 lung, liver nodes, soft tissues 23.32 144.6 BRAFi 8.2
#37 M1c high 2 brain, nodes 18.75 218.8 BRAFi 8.5
#38 M1c high 1 lung 26.98 94.5 PD1i 7.4
ipilimumab 23
median 2 (1e7) 20.85 (0.45e310.36) 135 (17e1125.3)
DTIC: dacarbazine; BRAFi: BRAF-inhibitor based therapy; PD1i: PD1 inhibitor; þ: dead.
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consistent across all treatment types (Fig. 2D). Thus, the
correlation between cfDNA and tumour burden was
maintained after treatment. Of note, one of the patients
presented only brain metastases, and even for this pa-
tient there was a correlation between cfDNA at baseline
(819.3 pg/mL) and following a partial response to dab-
rafenib (130.8 pg/mL).
We performed survival analysis by comparing the
patients with baseline cfDNA in the lower quartile
(<89 pg/mL, N Z 10), aggregated central quartiles
(89 pg/ml and <262.9 pg/mL, N Z 22) and upper
quartile (262.9 pg/mL N Z 11), including all 43 pa-
tients in this analysis. We found that overall survival
differed if cfDNA was low (22.7 months), intermediate(10.4 months) or high (8.5 months; P Z 0.032)
(Supplementary Fig. S3). To facilitate practical appli-
cation of our findings, we determined the optimal
baseline cfDNA concentration cut-off for survival
shorter than one year using a ROC-determined value of
89 pg/mL (corresponding to the lower quartile limit; area
under the curve Z 0.84) (Supplementary Fig. S4A).
Above this cut-off, patients presented a median overall
survival of 10.0 months, whereas below this cut-off,
patients presented an overall survival of 22.7
(P Z 0.009; Fig. 3A). Similarly, we analyzed serum
LDH, the standard prognostic biomarker for mela-
noma, and found that patients with LDH above the
upper normal limit (550U/L) had a worse prognosis (8.3
versus 18.8 months, P Z 0.014) (Fig. 3B).
Fig. 2. Plasma cfDNA is a biomarker for tumour burden in metastatic melanoma. (AeC) Scatter plots, showing the correlation between
baseline cfDNA concentration and pre-treatment tumour burden (A), renal glomerular filtration rate (B) and white cell count (C). Each
dot represents the value of a single patient; slanting lines are the regression lines. (D) Scatter plot showing the correlation between the
variations (the ratio between values at first re-assessment for treatment response and baseline) of cfDNA concentration and tumour
burden. Each dot is representative of the value of every single patient, slanting lines is the regression line. CR: complete response; PR:
partial response; SD: stable disease; PD: progressive disease; BRAFi: BRAF-inhibitors based therapy; DTIC: dacarbazine; PD1i: PD1
inhibitors.
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analysis to determine if cfDNA or LDH is the better
prognostic factor in our patients. Firstly we analyzed
cfDNA and LDH as continuous covariates without bias
produced by grouping and found that cfDNA was
significantly associated with the hazard of death (for
additional unit increase of cfDNA HR (95%
CI) Z 1.002 [1.001e1.004]; P Z 0.009) but LDH was
not (for additional unit increase of LDH, HR (95%
CI) Z 1.001 (1e1.002); 0.277). We then performed a
multivariate Cox regression analysis using cfDNA and
LDH as categorical variables (high versus. low, using
the cut-off of 89 pg/mL and the upper normal limit,
respectively) and cfDNA was confirmed to be a betterprognostic factor (HR Z 2.22 for patients with cfDNA
concentration 89 pg/mL; 95% CI 1.18e5.55,
P Z 0.004) (Supplementary Fig. S4B), than LDH
(HRZ 1.9 for patients with LDH  upper normal limit;
95% CI 1e7.9, P Z 0.213).
We next examined if the ratio of plasma cfDNA to
tumour volume (the cfDNA shedding coefficient,
defined as the ratio of cfDNA concentration in plasma
to tumour burden) impacted on prognosis. To assess if
patients with similar tumour burden had a worse
outcome if their baseline plasma cfDNA level was
relatively higher. We identified 8 pg/(mL*cm3) as the
optimal cut-off of the shedding coefficient for survival
shorter than one year (Supplementary Fig. 4B) and
Fig. 3. Plasma cfDNA is prognostic in metastatic melanoma patients.
(AeC)KaplaneMeier plots formelanoma patients showing overall
survival (OS) relative to baseline plasma total cfDNA concentra-
tions (A), plasma LDH levels (B) and the ratio between cfDNA and
tumour burden (C). In (A) the continuous line represents patients
with low baseline cfDNA concentration (<89 pg/mL, NZ 10), the
dashed line the high baseline cfDNA cohort (89 pg/ml,NZ 33). In
(B) the continuous line represents patients with low baseline LDH
value (NZ 27) and the dashed line patients with high baseline LDH
(N Z 16). In (C) the continuous line represents patients with low
baseline cfDNA shedding coefficient (NZ 19) and the dashed line
patients with high cfDNA shedding coefficient (NZ 19).
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coefficient (cfDNA/tumour volume8 pg/[mL*cm3]) had
worse prognosis than those with a low cfDNA shedding
coefficient (HR Z 2.7, 95% CI 1.1e6.7, P Z 0.029),with a median overall survival of 11.6 months and 27.9
months respectively (P Z 0.024) (Fig. 3C).
Finally, we compared the plasma cfDNA levels in
patients whose tumours presented with BRAF, NRAS or
KIT mutations, and also in tumours that were wild type
for all of the three genes, but did not find any correlation
between plasma total cfDNA concentration and muta-
tion group for these therapeutically important driver
oncogenes (F value 1.4, 3 degrees of freedom [DF],
P Z 0.254) (Fig. 4A). In addition, to determine if there
was a correlation between the plasma variant allele
frequency (VAF) for these specific driver oncogenes
(ctDNA) and the cfDNA in the patients’ plasma, we
compared VAF for BRAF, NRAS and KIT to total
cfDNA, and found that there was no correlation be-
tween these two values (rZ 0.16, PZ 0.162) (Fig. 4B).4. Discussion
In this study we demonstrated that there is a correlation
between plasma total cfDNA and tumour burden in
melanoma patients. By longitudinal sampling, we
further showed that the correlation between cfDNA and
tumour burden reflected the changes in tumour volumes
that occurred with therapeutic intervention. Critically,
we showed that baseline levels of total cfDNA were
prognostic for OS, and that patients whose tumours
released higher concentrations of cfDNA per unit vol-
ume had a worse prognosis. Thus, we concluded that
plasma total cfDNA is a reliable surrogate biomarker
for tumour burden and for changes that occur in tumour
burden during treatment. We also showed that in a
patient who presented only brain lesions, total cfDNA
reflected response to treatment, demonstrating that
metastatic sites in the central nervous system also
contribute to total ctDNA in the plasma.
Intriguingly, we did not observe a correlation be-
tween total cfDNA and individual mutant driver onco-
gene DNA levels (VAF) in the plasma. Notably, tumour
mass visualized by radiological investigations contains
not only cancer cells carrying specific driver mutations,
but also a vast array of stromal and inflammatory cells
that do not harbour those specific mutations. Both cell
populations are in constant turnover and are likely to
contribute disproportionally to the cfDNA in the blood.
Moreover, the proportion of cancer cells to stromal cells
within individual tumours will be different, further
affecting the amount of specific mutant DNA within the
total ctDNA for an individual patient. Furthermore,
there is considerable clonal variation between the cancer
cells within an individual tumour, and the evolutionary
selective pressure imposed by treatment and immuno-
surveillance can increase or decrease the cancer cell
clonality within disease localization, again affecting the
proportion of specific mutant to total ctDNA in the
blood.
Fig. 4. Plasma cfDNA is independent of driver oncogene mutation status. (A) Bars show the cfDNA concentration for metastatic melanoma
patients according to mutational status of the disease (BRAF mutated, NRAS mutated, KIT mutated or wild type for all these oncogenes).
(B) Scatter plot showing the correlation between cfDNA concentration and the variant allele frequency for BRAF, NRAS or KITmutation
measured in plasma of metastatic melanoma patients. Each dot represents the values of a single patient.
S. Valpione et al. / European Journal of Cancer 88 (2018) 1e98One of the limits of the present study is the relatively
small sample size, allowing the analysis of only two
covariates in the prognostic study. A larger number of
patients would be needed to include more prognostic
factors for melanoma. Furthermore, treatment options
for melanoma continue to improve over time, and
whether our findings remain valid with emerging treat-
ment options is unknown.
LDH is a well-established prognostic factor in
advanced melanoma, though why this is, is not clearly
understood. LDH level is routinely considered when
advising on treatment options and likely outcome, and
has maintained its relevance in the revised AJCC Stag-
ing System for melanoma [22]. When compared with
cfDNA prognostic value, LDH was not significant at
multivariate analysis. In contrast, despite the limited
sample size, we demonstrated that cfDNA was prog-
nostic for overall survival. If confirmed, this could lead
to cfDNA being established as a biomarker for prog-
nosis stratification and clinical decisions for metastatic
melanoma, and not being restricted to a specific muta-
tion could be used independent of genetic subtype. We
also identified a cut off baseline cfDNA concentration
that could stratify patients for a worse prognosis.
Although cut-off values are usually dependent on
experimental condition, our identified limit nevertheless
allowed us to endorse the prognostic value of cfDNA by
showing that patients with cfDNA levels below the cut-
off lived longer than patients with values above.5. Conclusions
In conclusion we show that cfDNA should be consid-
ered as a prognostic factor and a biomarker that could
be used as a surrogate for tumour burden and prognosis
with treatment in melanoma patients.Role of the funding source
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